It’s no secret that in the past decade the pharmaceutical industry has been spending more and more on research and getting less and less in return.
One consequence has been the many and varied attempts to remodel R&D operations and to pull in more innovation from universities and young biotech companies.
This is now raising the question of whether there is more value in sourcing early-stage assets externally than doing the work in house, challenging corporate R&D operations to show they are worth the huge amounts of cash invested in them.
In 2010 the consultants Deloitte set out to lend a hand in helping heads of R&D to justify the investment in R&D, carrying out a benchmark assessment of the value of all the drugs in the pipelines of the 12 leading pharma companies and how much had been spent on them to date.
To read the full, original article click on this link: Science|Business - The media network for research, industry and policy
